Sign in
4

Changes in Ownership

Dianthus Therapeutics, Inc. /DE/ Filed Acc 0001273351-26-000006

CHIEF ACCOUNTING OFFICER sold 20,000 shares at an average $101.38 ($2,027,646)

  • CHIEF ACCOUNTING OFFICER acquired 20,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

CARR EDWARD · CHIEF ACCOUNTING OFFICER

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2026-09-17 Exercise or conversion : show line 1 in the form 10b5-1 +20,000 $17.88 $357,600 20,000 D
2026-09-17 Sale : show line 2 in the form 10b5-1 −7,928 $100.43 $796,209 12,072 D
2026-09-17 Sale : show line 3 in the form 10b5-1 −6,771 $101.37 $686,376 5,301 D
2026-09-17 Sale : show line 4 in the form 10b5-1 −3,501 $102.39 $358,467 1,800 D
2026-09-17 Sale : show line 5 in the form 10b5-1 −1,100 $103.20 $113,520 700 D
2026-09-17 Sale : show line 6 in the form 10b5-1 −700 $104.39 $73,073 0 D
Open-market sales · 20,000 sh · avg $101.38 · $2,027,646

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-09-17 Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (Right to Buy) −20,000 43,818 D
Loading xslF345X06/ownership.xml…